Comparative Pharmacology
Head-to-head clinical analysis: ALOPRIM versus ZYLOPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOPRIM versus ZYLOPRIM.
ALOPRIM vs ZYLOPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations.
Allopurinol is a xanthine oxidase inhibitor that reduces the production of uric acid by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
300 mg orally once daily; may be increased to 600-800 mg/day in divided doses for severe gout.
100-300 mg orally once daily, maximum 800 mg/day.
None Documented
None Documented
Allopurinol: 1-2 h; Oxypurinol: 18-30 h (prolonged in renal impairment, up to 7 days in severe CKD)
Allopurinol: 1-2 hours; oxypurinol: 18-30 hours (prolonged to 48-72 hours in renal impairment). Clinical context: oxypurinol half-life determines dosing interval; dose adjustment required for CrCl < 20 mL/min.
Renal: ~70% (30% as allopurinol, 40% as oxypurinol); fecal: ~20%; biliary: minor (<5%)
Renal: allopurinol ~10% unchanged, oxypurinol ~70% unchanged; total renal elimination ~76% (allopurinol + oxypurinol); fecal/biliary: minor (~12-20% as allopurinol, ~3-5% as oxypurinol).
Category C
Category C
Xanthine Oxidase Inhibitor
Xanthine Oxidase Inhibitor